What a buyer sees
APPLECROFT CARE HOME LTD
Residential nursing care facilities · London · 04848475
116staff · FY2025
23years trading
—oldest owner on file
£417kcash at bank
Your turnover is on public record
filed£6.1Mfor the year to 2025
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff116
2021211 → 1162025
Cash at bank£417k
2021£1.0M → £417k2025
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£52,184in the middle half
£29,944£42,319£62,679
Debtor daysdays32in the top quarter
92150
Creditor daysdays21
71535
Stock daysdaysnot on your filings
62476
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 3
- A director resigned in the past yearA buyer will ask why, and will hear the answer from somewhere. Better from you.
- Debtor days run high for your tradeYours is 32 against 21 for the middle of 126 comparable companies. That gap is working capital a buyer has to fund on day one, and it comes off the price.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 1
- 23 years of trading on fileLongevity is the cheapest evidence there is that the business is not one contract.
What the register says
Owners
Nobody recorded with significant control.
Directors
- 50since 2018
- 37since 2025
- 50since 2026
- 59since 2026
| Year to | Filed | Turnover | Staff | Cash |
|---|---|---|---|---|
| 2025-12-31 | 2026-08-14 | £6.1M | 116 | £417k |
| 2023-12-31 | — | £5.5M | 117 | £116k |
| 2022-12-31 | — | £4.7M | 211 | £1.3M |
| 2021-12-31 | — | £4.1M | 211 | £1.0M |
A rough bracket, and why it is only that
0.4–0.9× sales£2.4M£5.5M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.